Powered by

iCAD Granted CE Mark Approval in Europe for PowerLook Tomo Detection 2.0 Artificial Intelligence Solution

Feb 28, 2018 - GlobeNewswire

Company's Innovative Breast Cancer Detection Product is Compatible with Hologic, GE and Siemens Digital Breast Tomosynthesis Systems Significantly Expanding iCAD's Global Market Opportunity

VIENNA, Austria, March 01, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in medical technology providing innovative cancer detection and therapy solutions, today announced receipt of CE Mark approval for PowerLook Tomo Detection 2.0, the company's second deep-learning based com...